close
References
  1. Chapman AB, Devuyst O, Eckardt KU, et al; Conference Participants. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015;88(1):17-27.
  2. Finnigan NA, Leslie SW. Polycystic kidney disease in adults. In: StatPearls. Treasure Island, FL: StatPearls Publishing. January 2020. Last updated August 10, 2020.
  3. Willey C, Kamat S, Stellhorn R, Blais J. Analysis of nationwide data to determine the incidence and diagnosed prevalence of autosomal dominant polycystic kidney disease in the USA: 2013-2015. Kidney Dis (Basel). 2019;5(2):107-117.
  4. Chapman AB, Devuyst O, Eckardt K-U, et al; Conference Participants. Autosomal dominant polycystic kidney disease (ADPKD): report from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-ADPKD-Supplemental-Full-Report-FINAL.pdf. Accessed January 25, 2019.
  5. Reed B, McFann K, Kimberling WJ, et al. Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am J Kidney Dis. 2008;52(6):1042-1050.
  6. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287-1301.
  7. Cornec-Le Gall E, Audrézet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24(6):1006-1013.
  8. Chebib FT, Sussman CR, Wang X, Harris PC, Torres VE. Vasopressin and interactive calcium cyclic AMP and purinergic signaling in polycystic kidney disease. Nat Rev Nephrol. 2015;11(8):451-464.
  9. Srivastava A, Patel N. Autosomal dominant polycystic kidney disease. Am Fam Physician. 2014;90(5):303-307.
  10. Torres VE, Chapman AB, Devuyst O, et al; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407-2418.
  11. Saigusa T, Bell PD. Molecular pathways and therapies in autosomal-dominant polycystic kidney disease. Physiology (Bethesda). 2015;30(3):195-207.
  12. Zheleznova NN, Wilson PD, Staruschenko A. Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells. Biochim Biophys Acta. 2011;1812(10):1301-1313.
  13. Chebib FT, Perrone RD, Chapman AB, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29(10):2458-2470.
  14. Müller RU, Haas CS, Sayer JA. Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan. Clin Kidney J. 2018;11(1):62-69.
  15. Magistroni R, Corsi C, Martí T, Torra R. A review of the imaging techniques for measuring kidney and cyst volume in establishing autosomal dominant polycystic kidney disease (ADPKD) progression. Am J Nephrol. 2018;48(1):67-78.
  16. National Institute of Diabetes and Digestive and Kidney Diseases. Autosomal dominant polycystic kidney disease. www.niddk.nih.gov/health-information/kidney-disease/polycystic-kidney-disease/autosomal-dominant-pkd. Last updated January 2017. Accessed December 19, 2020.
  17. Spithoven EM, Kramer A, Meijer E, et al; ERA-EDTA Registry; EuroCYST Consortium; EuroCYST Consortium; WGIKD. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int. 2014;86(6):1244-1252.
  18. Yrad ALS, Humphreys C. Primary care perspectives in autosomal dominant polycystic kidney disease. Nurse Pract. 2017;42(6):8-11.
  19. Irazabal MV, Torres VE. Total kidney volume and autosomal dominant polycystic kidney disease: a long-standing relationship. Am J Nephrol. 2018;48(1):65-66.
  20. Grantham JJ, Torres VE, Chapman AB, et al; CRISP Investigators. Volume progression in polycystic kidney disease. N Engl J Med. 2006.;354(20):2122-2130.
  21. Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7(3):479-486.
  22. Yu ASL, Shen C, Landsittel DP, et al; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in autosomal dominant polycystic kidney disease. Kidney Int. 2018;93(3):691-699.
  23. Perrone RD, Mouksassi MS, Romero K, et al. Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep. 2017;2(3):442-450.
  24. Turco D, Severi S, Mignani R, Aiello V, Magistroni R, Corsi C. Reliability of total renal volume computation in polycystic kidney disease from magnetic resonance imaging. Acad Radiol. 2015;22(11):1376-1384.
  25. Chebib FT, Torres VE. Recent advances in the management of autosomal dominant polycystic kidney. Clin J Am Soc Nephrol. 2018;13(11):1765-1776.
  26. Irazabal MV, Rangel LJ, Bergstralh EJ, et al; CRISP Investigators. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160-172.
  27. Mayo Foundation and Medical Education and Research. Imaging classification of ADPKD: a simple model for selecting patients for clinical trials. Mayo ADPKD class calculator. www.mayo.edu/research/documents/pkd-center-adpkd-classification/doc-20094754. Accessed December 17, 2020.
  28. Bae KT, Shi T, Tao C, et al; HALT PKD Consortium. Expanded imaging classification of autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2020;31(7):1640-1651.
  29. Schrier RW, Abebe KZ, Perrone RD, et al; HALT-PKD Trial Investigators. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2255-2266.
  30. EAF co-chairs, Harris T, Sandford R; EAF members; Roundtable participants. European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care. Nephrol Dial Transplant. 2018;33(4):563-573.
  31. Jynarque (tolvaptan) prescribing information. Otsuka Pharmaceutical Co, Ltd; 2020.
  32. Torres VE, Chapman AB, Devuyst O, et al; REPRISE Trial Investigators. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930-1942.
  33. Blair HA. Tolvaptan: a review in autosomal dominant polycystic kidney disease. Drugs. 2019;79(3):303-313.
  34. Torres VE, Higashihara E, Devuyst O, et al; TEMPO 3:4 Trial Investigators. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol. 2016;11(5):803-811.
  35. Morris JH, Bohm NM, Nemecek BD, et al. Rapidity of correction of hyponatremia due to syndrome of inappropriate secretion of antidiuretic hormone following tolvaptan. Am J Kidney Dis. 2018;71(6):772-782.
  36. Cárdenas A, Ginès P, Marotta P, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol. 2012;56(3):571-578.
  37. Boyer TD. Tolvaptan and hyponatremia in a patient with cirrhosis. Hepatology. 2010;51(2):699-702.